Renal Cell Carcinoma Market Report 2025

This Renal Cell Carcinoma market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The renal cell carcinoma market size has grown strongly in recent years. It will grow from $0.69 billion in 2024 to $0.74 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of kidney cancer, a growing geriatric population, wider adoption of targeted therapies, enhanced awareness of cancer screening, improvements in healthcare infrastructure, and a rise in investments in oncology research and development.

The renal cell carcinoma market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. Looking forward, the growth in the forecast period is expected to be driven by the growing adoption of personalized medicine, increasing awareness about early cancer detection, rising healthcare investments in oncology, better access to healthcare, and a surge in clinical trials and research focused on novel therapies. Key trends for the forecast period include the integration of artificial intelligence for precision diagnostics, the development of targeted therapies, innovations in immunotherapy, advancements in biomarker identification, the adoption of minimally invasive surgical techniques, and improvements in imaging technologies.

The increasing geriatric population is anticipated to drive the expansion of the renal cell carcinoma market. The elderly, typically defined as individuals aged 65 and above, often have unique healthcare and social needs. The growth in this demographic is attributed to advancements in healthcare, improved nutrition, and longer life expectancy. Renal cell carcinoma (RCC) is becoming more common among older adults, underscoring the need for specialized screening and treatment approaches for this group. For example, in January 2024, a report by the Population Reference Bureau, a US-based non-profit organization, predicted that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Consequently, the aging population is contributing to the growth of the renal cell carcinoma market.

Companies in the renal cell carcinoma market are focusing on technological advancements, particularly in the use of artificial intelligence (AI) to enhance cancer diagnosis and treatment. AI-powered solutions, such as those designed to analyze kidney biopsies, are being developed to improve diagnostic accuracy, streamline procedures, and optimize patient outcomes. These AI tools use machine learning algorithms and computer vision to assist pathologists and nephrologists in evaluating kidney tissue samples. For example, in March 2024, Aiosyn, a software company based in the Netherlands, introduced the NephroPath platform, an AI-powered solution for kidney biopsy analysis. NephroPath employs computational pathology algorithms to analyze histological biomarkers in kidney biopsies, including identifying tissue types, measuring interstitial fibrosis, and assessing glomeruli. This AI-driven technology ensures consistent, detailed, and reproducible scoring of renal pathology biomarkers, addressing limitations of traditional scoring methods and reducing observer bias.

In October 2024, Arcus Biosciences, a US-based biotechnology firm, partnered with AstraZeneca plc to investigate the combination of casdatifan (AB521) and volrustomig for patients with clear cell renal cell carcinoma (ccRCC). The partnership aims to advance treatment for ccRCC by developing a new drug combination, combining the expertise of both companies to accelerate development and improve patient outcomes. AstraZeneca plc, a UK-based pharmaceutical company, is known for its focus on oncology treatments and diagnoses.

Major players in the renal cell carcinoma market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, Fresenius Kabi AG, GSK plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc. (Mylan N.V.), Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Cipla Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Exelixis Inc., Nektar Therapeutics.

North America was the largest region in the renal cell carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in renal cell carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the renal cell carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the renal tubules, which are responsible for filtering waste and producing urine. The cancer develops when kidney cells become abnormal and begin growing uncontrollably, forming a tumor that can impair the kidney's ability to filter waste and produce urine.

The primary types of renal cell carcinoma include clear cell RCC, papillary RCC, and chromophobe RCC. Clear cell RCC is the most common form of kidney cancer, arising in the kidney's blood-filtering tubules. Microscopically, the cancer cells appear clear or pale due to the accumulation of lipids and carbohydrates. Diagnosis typically involves a combination of urine and blood tests, computed tomography (CT) scans, ultrasounds, nephrectomy, and biopsies. Treatment options include surgery, targeted therapies, chemotherapy, ablation, medications, and other methods, serving a variety of settings such as hospitals, specialty clinics, home care, and other healthcare providers.

The renal cell carcinoma market research report is one of a series of new reports that provides renal cell carcinoma market statistics, including the renal cell carcinoma industry's global market size, regional shares, competitors with a renal cell carcinoma market share, detailed renal cell carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the renal cell carcinoma industry. This renal cell carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The renal cell carcinoma market consists of revenues earned by entities by providing services such as CT scans, ultrasounds, chemotherapy and targeted therapy, immunotherapy, and supportive care and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The renal cell carcinoma market also includes sales of needle biopsy systems, laser ablation devices, biopsy trays and kits, and biopsy specimen containers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.